Merck Announces Second-Quarter 2017 Dividend
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.47 per share of the company ’s common stock for the second
quarter of 2017. Payment will be made on April 7, 2017 to shareholders
of record at the close of business on March 15, 2017.About MerckLanguage:
EnglishContact: MerckMedia:Lainie Keller, 908-236-5036orClaire Gillespie, 267-305-0932orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ti...
Source: Merck.com - Corporate News - February 28, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses
Discussions Between Health Care Professionals and Patients to Help Them Understand Their Increased Risk For Pneumococcal Pneumonia/Pneumococcal Disease, Flu and Hepatitis BKENILWORTH, N.J.--(BUSINESS WIRE)--Many adults with diabetes are unaware of their increased risk for
certain serious illnesses, including pneumococcal pneumonia/pneumococcal
disease, flu and hepatitis B. This is according to a recent national,
online consumer awareness survey sponsored by Merck (NYSE:MRK), known as
MSD outside the United States and Canada, and the American Diabetes
Association, and conducted by Harris Poll.La...
Source: Merck.com - Corporate News - February 28, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Diabetes MSD NYSE:MRK Source Type: news
Merck ’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the launch of IL ÚM Health Solutions, which provides
enterprise-wide disease management tools and services to enable improved
outcomes for patients with infectious diseases, such as sepsis and
pneumonia, while supporting antimicrobial stewardship initiatives. ILÚM
operates independently from Merck’s pharmaceutical and vaccine products
businesses as part of Merck’s Healthcare Services& Solutions (HSS)
group.Language:
Engli...
Source: Merck.com - Corporate News - February 16, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK ILUM MSD NYSE:MRK Source Type: news
Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care
Dateline City:
KENILWORTH, N.J. Alliance Aims to Reduce Disparities in Access to High-Quality Cancer CareKENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation), announced today the selection of the
six program sites and National Program Office forming theAlliance
to Advance Patient-Centered Cancer Care (theAlliance).
With $15 million in funding from the Foundation over five years, theAlliance
aims to increase timely access to patient-centered cancer care for
vulnerable and underserved populations in the United States.Language:
EnglishContact: For Merck:Media:L...
Source: Merck.com - Corporate News - February 9, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK Merck Foundation MSD NYSE:MRK Source Type: news
FDA Accepts Two sBLAs for Merck ’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings
Dateline City:
KENILWORTH, N.J. KEYTRUDA Also Receives Breakthrough Therapy Designation for Second-Line Treatment Based on KEYNOTE-045, Which Includes Primary Endpoints of Overall Survival and Progression-Free SurvivalKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review two supplemental Biologics License Applications
(sBLAs) for KEYTRUDA® (pembrolizumab), the company ’s
anti-PD-1 therapy, in patients with locally advanced or metastatic
urotheli...
Source: Merck.com - Corporate News - February 3, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news
Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results
Dateline City:
KENILWORTH, N.J. Fourth-Quarter 2016 Worldwide Sales Were $10.1 Billion, a Decrease of 1 Percent, Including a 1 Percent Negative Impact from Foreign Exchange; Full-Year 2016 Worldwide Sales Were $39.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Fourth-Quarter 2016 GAAP EPS Was $0.42; Fourth-Quarter Non-GAAP EPS Was $0.89; Full-Year 2016 GAAP EPS Was $2.04; Full-Year Non-GAAP EPS Was $3.78 2017 Financial Outlook Expects Full-Year 2017 GAAP EPS to be Between $2.47 and $2.62; Expects Non-GAAP EPS to be B...
Source: Merck.com - Corporate News - February 2, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
European Commission Approves KEYTRUDA ® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations
Dateline City:
KENILWORTH, N.J. Approval Based on Data Showing Improved Overall Survival and Progression-Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy Approved in Europe for Previously Untreated Patients with Metastatic NSCLCKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission has approved KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, for the first-line
treatment of metastatic non-small cell lung cancer (NSCLC) in adults
whose tumors have high...
Source: Merck.com - Corporate News - January 31, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NSCLC NYSE:MRK Source Type: news
Pro Football Hall of Famer and Cancer Survivor Jim Kelly Teams Up with Merck and Leading Cancer Organizations to Launch Your Cancer Game Plan
Dateline City:
KENILWORTH, N.J. Kelly Provides His “Game Plan” for Navigating Head and Neck CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Head and neck cancer survivor and Pro Football Hall of Famer Jim Kelly
is sharing his personal experience as part ofYour Cancer Game Plan,
a new awareness campaign focused on helping people with cancer and their
loved ones tackle their emotional, nutritional and communication needs.
Kelly, one of the toughest quarterbacks to have played Pro Football,
successfully handled the gridiron with his motto ‘Kelly Tough’ – a motto
that took on new meaning...
Source: Merck.com - Corporate News - January 25, 2017 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK cancer Jim Kelly MSD NYSE:MRK Source Type: news
Merck Announces Settlement and License Agreement Resolving KEYTRUDA ® (pembrolizumab) Patent Litigation
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada),
and certain of its affiliates, today announced it agreed to enter into a
settlement and license agreement with Bristol-Myers Squibb Company and
Ono Pharmaceutical Co., Ltd., resolving the worldwide patent
infringement litigation related to the use of an anti-PD-1 antibody for
the treatment of cancer, such as KEYTRUDA® (pembrolizumab).Language:
EnglishContact: Merck Media:Pamela Eisele, 267-305-3558Claire Gillespie, 267-305-0932or Investors:Ter...
Source: Merck.com - Corporate News - January 20, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers
Dateline City:
DAVOS, Switzerland Represents a Critical Step toward Meeting the Sustainable Development Goals for Women, Children and Adolescent HealthDAVOS, Switzerland--(BUSINESS WIRE)--MSD, known as Merck& Co., Inc., Kenilworth, N.J., U.S.A., inside the
United States and Canada, announced today its $10 million commitment to
the Global Financing Facility (GFF) in support ofEvery Woman Every
Child to improve maternal and child health in low- and
lower-middle-income countries worldwide through itsMSD for Mothers
initiative.Language:
EnglishContact: Media: MSD for MothersLain...
Source: Merck.com - Corporate News - January 19, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK GFF Global Financing Facility MSD MSD for Mothers NYSE:MRK World Bank Source Type: news
Merck Foundation Grant Expands Project ECHO ® in Vietnam and India
Dateline City:
KENILWORTH, N.J. Project Increases Access to Specialty Care for Complex, Chronic ConditionsKENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation) and the Extension for Community
Healthcare Outcomes (ECHO) Institute ™ at the University of New Mexico
Health Sciences Center announced today that the Foundation has provided
a grant of $7 million over five years to support the expansion ofProject
ECHO® to improve access to specialty care for complex,
chronic conditions, such as: hepatitis C, HIV, tuberculosis, and
non-communicable diseases, including diabete...
Source: Merck.com - Corporate News - January 18, 2017 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK Merck Foundation MSD NYSE:MRK Source Type: news
Merck to Participate at the 35th Annual J.P. Morgan Healthcare Conference
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Kenneth C. Frazier, chairman and chief executive
officer, and Dr. Roger M. Perlmutter, president, Merck Research
Laboratories, are scheduled to participate at the 35th Annual
J.P. Morgan Healthcare Conference in San Francisco on Jan. 9, 2017 at
4:00 p.m. PST (7:00 p.m. EST).Language:
EnglishContact: Media:Lainie Keller, 908-236-5036orClaire Gillespie, 267-305-0932orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-18...
Source: Merck.com - Corporate News - January 6, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK JP Morgan MSD NYSE:MRK Source Type: news
Merck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings Conference Call on February 2
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
will hold its fourth-quarter and full-year 2016 sales and earnings
conference call with institutional investors and analysts at 8:00 a.m.
EST on Thursday, Feb. 2. During the call, company executives will
provide an overview of Merck ’s performance for the quarter and year.Language:
EnglishContact: MerckMedia:Lainie Keller, (908) 236-5036Claire Gillespie, (267) 305-0932orInvestor:Teri Loxam, (908) 740-1986Amy Klug, (908) 740-1898Ticker Slug:Tic...
Source: Merck.com - Corporate News - January 3, 2017 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK earnings MSD NYSE:MRK Source Type: news
European Medicines Agency ’s CHMP Recommends Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor...
Dateline City:
KENILWORTH, N.J. Opinion Based on Findings from KEYNOTE-024 Trial, Which Showed Superior Overall Survival and Progression Free Survival with KEYTRUDA Compared to Chemotherapy First Anti-PD-1 Therapy to Receive a CHMP Positive Opinion for Previously Untreated Patients with Metastatic NSCLCKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of KEYTRUDA ®...
Source: Merck.com - Corporate News - December 16, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK CHMP Keytruda MSD NSCLC NYSE:MRK Source Type: news
Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck ’s KEYTRUDA® (pembrolizumab) and Eisai’s HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS
Dateline City:
KENILWORTH, N.J.& WOODCLIFF LAKE, N.J.KENILWORTH, N.J.& WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Eisai Inc. today announced new interim data investigating Merck ’s
anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in combination
with Eisai ’s microtubule dynamics inhibitor, HALAVEN®
(eribulin), in patients with metastatic triple-negative breast cancer
(TNBC).Language:
EnglishContact: Media:MerckPamela Eisele, 267-305-3558orKim Hamilton, (908) 740-1863orEisai Inc.Laurie Landau, 201-746-251...
Source: Merck.com - Corporate News - December 12, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Eisai HALAVEN Keytruda MSD NYSE:MRK Source Type: news
